No Data
No Data
No Data
No Data
No Data
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items from the first two weeks of April 2024.See previous edition Psychedelics Headlines: A Form Of Life, Treati
BenzingaApr 17 09:13 ET
Express News | Psyence Biomedical Ltd: Anticipates Enrolling First Subject in Q2 of 2024 and Expects Primary Endpoint Results to Be Available in 2025
Moomoo 24/7Apr 17 08:06 ET
Express News | Psyence Biomed Announces Phase Iib Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (Anzctr)
Moomoo 24/7Apr 17 08:00 ET
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Yahoo FinanceApr 16 11:01 ET
Express News | Psyence Biomed Australian Subsidiary, Psyence Australia Partners With Fluence And INGENū CRO To Train Research Therapists For Phase IIb Psilocybin Trial
Moomoo 24/7Apr 8 08:14 ET
Psyence Biomed Partners With Fluence and INGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that its Australian subsidiary, Psyence Australia Pty Ltd. ("Psyence Australia"), has
GlobeNewswireApr 8 08:00 ET
No Data
No Data
LDG_Jeff : Have you entered ?
TrytosaveabitOP LDG_Jeff: Just watching to see if it actually gets any significant volume for now! GL